According to diabetes news, the new diabetes drug Onglyza will cost the same amount as Januvia, the market-leading drug created by Merck. The pricing will plunge the two drugs into direct competition.
Onglyza, made by AstraZeneca and Bristol-Myers Squibb, serves to increase the ability of the body to lower high blood sugar levels. The drug is part of a class of diabetes drugs called DPP-4 inhibitors.
People with diabetes need to maintain average blood glucose levels to lower the risk of complications . Januvia, experts say, will continue to dominate the DPP-4 market. Onglyza was recently approved by the Food and Drug Administratio, the most important stage in bringing new diabetes treatments to market.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…